CHO Pharma (ROCO:6586) Total Debt per Share: NT$0.03 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6586 CHO Pharma Inc ROCO:6586
31 GF Score
Price NT$101.00
! 2 Warning Signs
View Full Analysis

What is CHO Pharma Total Debt per Share?

CHO Pharma ROCO:6586 -4.76% 31 Total Debt per Share is NT$0.03 as of Jun. 2026. GuruFocus rates ROCO:6586 with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

NT$0.03 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. CHO Pharma's Total Debt Per Share for the quarter that ended in Jun. 2026 was NT$0.03.


CHO Pharma Total Debt per Share Historical Data

* Premium members only.

The historical data trend for CHO Pharma's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CHO Pharma Total Debt per Share Chart

CHO Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.06 0.00 0.14 0.07

CHO Pharma Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.14 0.10 0.07 0.03
ROCO:6586
31GF Score
CHO Pharma Inc ROCO:6586
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CHO Pharma Total Debt per Share Calculation

CHO Pharma's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

CHO Pharma's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of NT$0.03 mean?
CHO Pharma (ROCO:6586) has a Total Debt per Share of NT$0.03 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on CHO Pharma and its competitors.
Is CHO Pharma's Total Debt per Share too high?
CHO Pharma's current Total Debt per Share is NT$0.03. Overall, CHO Pharma has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does CHO Pharma's Total Debt per Share compare to VRTX and REGN?
CHO Pharma's Total Debt per Share of NT$0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on CHO Pharma and its competitors. CHO Pharma's current Total Debt per Share is NT$0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CHO Pharma stock overvalued right now?
CHO Pharma (ROCO:6586) has a current Total Debt per Share of NT$0.03. The current Total Debt per Share is NT$0.03. CHO Pharma's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For CHO Pharma (ROCO:6586), the current Total Debt per Share is NT$0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CHO Pharma Business Description

Address Lane 130, Sec. 1 Academia Road, 7th Floor, Building C, No.99, Nangang, Taipei, TWN, 115202
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
31GF Score

Get the complete analysis for ROCO:6586

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$101.00
Price